

# Enhancing TCR<sup>tg</sup> T cell therapy efficacy in solid tumors using mRNA-based vaccination

Janna Krueger,<sup>1</sup> Janne Ruotsalainen,<sup>1</sup> Johannes Lutz,<sup>1</sup> Ronja Bick,<sup>1</sup> Regina Heidenreich<sup>1</sup>

<sup>1</sup> CureVac SE, Friedrich-Miescher-Straße 15, Tübingen, Germany


## BACKGROUND AND AIMS

- In recent years, adoptive T cell therapy (ACT) has demonstrated remarkable efficacy against B-cell malignancies.
  - However, clinical benefit in solid tumors remains limited and short-lasting.
  - ACT faces several challenges in solid tumors such as inadequate tumor penetration and limited functionality and durability of the T-cell response.
- To address the limitations, we explored mRNA vaccination as a strategy to enhance the efficacy of TCR transgenic (TCR<sup>tg</sup>) T cell ACT in the MC38-OVA mouse model.
  - We hypothesized that an OVA-mRNA vaccine could activate both transferred and endogenous T cells and thus enhance antitumor efficacy in comparison to ACT alone.

## RESULTS

### 1. mRNA VACCINATION DELAYS TUMOR GROWTH


- mRNA vaccination against the model tumor antigen OVA temporarily delays MC38-OVA tumor growth, thus allowing assessment of potential synergies with ACT.



**Treatment scheme.** MC38-OVA expressing tumor cells were inoculated into CD45.1 C57BL/6 mice. Tumor-bearing mice were kept untreated or vaccinated with a mRNA-based vaccine encoding Ovalbumin.

### 2. IDENTIFICATION OF SUBOPTIMAL T CELL DOSE FOR ACT

- Adoptive transfer of a low dose of activated ova-specific OT-I TCR<sup>tg</sup> T cells has limited anti-tumoral efficacy in MC38-OVA model.




**Treatment regimen.** MC38-OVA tumor cells were inoculated into CD45.1 C57BL/6 mice. Tumor-bearing mice were kept untreated or treated with  $2 \times 10^6$  (high dose) or  $0.1 \times 10^6$  (low dose) of activated OT-I T cells.

**Tumor growth curves.** ACT with high dose of OT-I T cells resulted in 10/10 complete responders, while low dose resulted only in 6/10 complete responders, incl. tumor regrowth after remission.

### 3. COMBINATION OF ACT AND EARLY VACCINATION INDUCES AN EFFICIENT AND LONG-LASTING ANTI-TUMORAL RESPONSE


- Transfer of a low dose of OT-I T cells combined with early vaccination (one day after ACT) resulted in complete tumor regression with long-lasting efficacy.
- In contrast, transfer of a low dose of OT-I T cells combined with late vaccination (eight day after ACT) resulted in tumor regression in most but not all mice.



#### Treatment regimen.

MC38-OVA tumor cells were inoculated into CD45.1 C57BL/6 mice.


Tumor-bearing mice were kept untreated or treated with  $0.1 \times 10^6$  (low dose) or  $2 \times 10^6$  cells (high dose) activated OT-I T cells (CD45.2\*).




**Tumor growth curves.** (i) Low-dose ACT with vaccination starting one day post ACT achieved tumor regression in all mice, while low-dose ACT alone resulted in 6/10 complete responders. High-dose ACT achieved also tumor regression in all mice. (ii) Vaccination starting eight days post ACT eradicated tumors in 7/10 mice.

### 4. VACCINATION EXPANDS TRANSFERRED OT-I T CELLS IN BLOOD

- Vaccination increases number of transferred OT-I T cells in the periphery.
- Vaccination 54 days post ACT expands transferred T cells both in mice that have already been vaccinated multiple times after ACT and mice that have not been vaccinated after ACT.
- Early vaccination + low ACT dose yields 100% survival in the MC38-OVA model.



**Transferred OT-I T cells in the periphery and mouse survival.** Low amount of transferred OT-I T cells could be boosted by vaccinations (day 11, pink and violet bar). 25 days post last vaccination, the OT-I T cells were not anymore observed in the circulation (day 40). Vaccination at day 54 again expanded the transferred OT-I T cells (day 59, pink and violet bar). One vaccination 54 days post ACT could expand peripheral OT-I T cells in mice (day 59, blue and yellow bars).




**Phenotypic analysis of transferred OT-I T cells in periphery.** (i) Vaccination shifts differentiation of transferred OT-I T cells to PD-1<sup>+</sup> TIM3<sup>+</sup> Slamf6<sup>+</sup> cells at day 11. (ii) Generation of SLECS (short lived effector cells) and MPECS (memory precursor effector cells) upon combination therapy.

**Analysis of endogenous antigen-specific CD4<sup>+</sup> T cells in the spleen and therapy efficacy.** Polyfunctional antigen-specific CD4<sup>+</sup> T cells (teal) are mainly expanded after multiple vaccinations (iii). Early OVA-mRNA vaccination (starting day 1) rescued the efficacy of the low OT-I dose (iv).

### 5. VACCINATION INCREASES INFILTRATION AND CYTOTOXICITY OF THE TRANSFERRED T CELLS

- Vaccine-mediated increase in number of OT-I T cells in the periphery is accompanied by increase of OT-I T cells in the tumor.
- Vaccination promotes a cytotoxic phenotype in the tumor infiltrating OT-I T cells.



**OT-I T cell expansion, tumor infiltration and phenotype of the infiltrated T cells.** Vaccination increases the number of OT-I T cells in the blood (i) and the tumor (ii), and increases GZMB expression on tumor-infiltrating T cells (iii).

## CONCLUSION

- Our preclinical studies investigated the effects of mRNA vaccination on transferred TCR<sup>tg</sup> and endogenous T cells, as well the impact of vaccination on tumor growth, mouse survival and T cell infiltration into the tumors.
- The obtained data demonstrate a significant improvement in adoptive TCR<sup>tg</sup> T cell therapy efficacy, when combined with an mRNA vaccine.

## KEY TAKEAWAYS




- ACT with CAR T cells has revolutionized the treatment of B cell malignancies, and ACT using TCR<sup>tg</sup> T cells has shown promise in several cancer types.
- ACT of solid cancers suffers from insufficient infiltration, effector functions and persistence of the T cells.



- This preclinical work utilized the MC38-OVA mouse tumor model to test whether the efficacy of TCR<sup>tg</sup> T cell ACT could be increased by mRNA vaccination.

MC38-OVA + OT-I ACT + OVA-mRNA based vaccine



- Tumor growth was suppressed, and mouse survival increased by the addition of an mRNA vaccine into the ACT regimen.
- Vaccine promoted expansion, infiltration and effector phenotype of the transferred T cells.
- Vaccination also increased the number of endogenous, antigen specific polyfunctional CD4<sup>+</sup> T cells.



- Combining mRNA vaccination with ACT increased therapy efficacy in comparison to monotherapies and established a long lasting immunosurveillance.
- The combinatorial approach paves way for improved ACT outcomes against solid tumors.